ReviewTheranostics2020
Open access · goldAbstract readReview
In one paragraph
Review in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.Arthritis research & therapy · 2026Trial
- Diagnostic Performance of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Safety, Dosimetry, and Feasibility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged withMolecular imaging · 2022Trial
- Safety, Biodistribution, and Radiation Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- A microdose clinical trial to evaluate [European journal of nuclear medicine and molecular imaging · 2021Trial
- Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy.EJNMMI reports · 2026Article
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis.European journal of nuclear medicine and molecular imaging · 2025Article
- Development and Evaluation of a Vinyl Sulfone-Based Fluorine-18 Labeling Method for Constructing PSMA-targeted Prostate Cancer Imaging Agents.Molecular imaging and biology · 2025Article
- Pelvic lymph node management in prostate cancer: a narrative review.Prostate international · 2025Review
- Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.International journal of molecular sciences · 2025Review
- PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.Targeted oncology · 2025Review
- PrognosticEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.Radiology. Imaging cancer · 2025Article
- Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.BMC medicine · 2025Article
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- The [18F] F-PSMA Probe: Chemical Perspectives.Current medicinal chemistry · 2025Review
- Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.Molecules (Basel, Switzerland) · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 3 countries.
Rudolf A WernerDepartment of Nuclear Medicine, Hannover Medical School, Hannover, Germany.
Thorsten DerlinDepartment of Nuclear Medicine, Hannover Medical School, Hannover, Germany.
Constantin LapaDepartment of Nuclear Medicine, University Hospital Würzburg, Germany.
Sara SheikbahaeiThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Takahiro HiguchiDepartment of Nuclear Medicine, University Hospital Würzburg, Germany.
Frederik L GieselDepartment of Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany.
Spencer BehrDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA.
Alexander DrzezgaDepartment of Nuclear Medicine, University Hospital Cologne, Germany.
Hiroyuki KimuraDepartment of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan.
Andreas K BuckDepartment of Nuclear Medicine, University Hospital Würzburg, Germany.
Frank M BengelDepartment of Nuclear Medicine, Hannover Medical School, Hannover, Germany.
Martin G PomperThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael A GorinThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven P RoweThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins Medicine · USMedizinische Hochschule Hannover · DEUniversitätsklinikum Würzburg · DEKyoto Pharmaceutical University · JPOkayama University · JPUniversity Hospital Cologne · DEUniversity Hospital Heidelberg · DEUniversity of California, San Francisco · US
Funding
Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8MPSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2MSmall Molecule PSMA-Targeted Alpha TherapyR01CA184228 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G, ZALUTSKY, MICHAEL ROD · 2014 to 2023
$3.6MPSMA Directed Imaging of Prostate Cancer Focus on Androgen Receptor DynamicsU01CA183031 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEWEESE, THEODORE L, POMPER, MARTIN G · 2015 to 2017
$1.2MNCI NIH HHS R01 CA134675NCI NIH HHS R01 CA184228NCI NIH HHS U01 CA183031NIBIB NIH HHS P41 EB024495
Abstract
Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
Indexed as
Molecular ImagingPositron-Emission TomographyAntigens, SurfaceFluorine RadioisotopesGlutamate Carboxypeptidase IIHumansMaleProstatic NeoplasmsRadiopharmaceuticalsAntigens, SurfaceFluorine-18Fluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticals18F68GaPETprostate cancerprostate-specific membrane antigenPSMARadiofluorineradioligand therapytheranostics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.